{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T03:30:37Z","timestamp":1792899037936,"version":"4.5.0"},"reference-count":89,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,1,31]],"date-time":"2017-01-31T00:00:00Z","timestamp":1485820800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Cancer"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.trecan.2016.12.005","type":"journal-article","created":{"date-parts":[[2017,1,18]],"date-time":"2017-01-18T21:46:18Z","timestamp":1484775978000},"page":"137-148","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":96,"title":["Tumor\u2013Host Cell Interactions in Ovarian Cancer: Pathways to Therapy Failure"],"prefix":"10.1016","volume":"3","author":[{"given":"Elke","family":"Pogge von Strandmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silke","family":"Reinartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Wager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3339-4248","authenticated-orcid":false,"given":"Rolf","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.trecan.2016.12.005_bib0005","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.2353\/ajpath.2010.100105","article-title":"Ovarian cancer development and metastasis","volume":"177","author":"Lengyel","year":"2010","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.trecan.2016.12.005_bib0010","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/nrc3144","article-title":"Rethinking ovarian cancer: recommendations for improving outcomes","volume":"11","author":"Vaughan","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.trecan.2016.12.005_bib0015","doi-asserted-by":"crossref","first-page":"256","DOI":"10.3389\/fonc.2013.00256","article-title":"Getting to know ovarian cancer ascites: opportunities for targeted therapy-based translational research","volume":"3","author":"Ahmed","year":"2013","journal-title":"Front. Oncol."},{"key":"10.1016\/j.trecan.2016.12.005_bib0020","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/nrc4019","article-title":"Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer","volume":"15","author":"Bowtell","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.trecan.2016.12.005_bib0025","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrc3432","article-title":"Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research","volume":"13","author":"Kipps","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.trecan.2016.12.005_bib0030","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s13059-016-0956-6","article-title":"A transcriptome-based global map of signaling pathways in the ovarian cancer microenvironment associated with clinical outcome","volume":"17","author":"Reinartz","year":"2016","journal-title":"Genome Biol."},{"key":"10.1016\/j.trecan.2016.12.005_bib0035","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.canlet.2012.10.023","article-title":"Ovarian cancer stem cells: working towards the root of stemness","volume":"338","author":"Foster","year":"2013","journal-title":"Cancer Lett."},{"key":"10.1016\/j.trecan.2016.12.005_bib0040","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1158\/1535-7163.MCT-10-0788","article-title":"Ovarian cancer stem cell-like side populations are enriched following chemotherapy and overexpress EZH2","volume":"10","author":"Rizzo","year":"2011","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.trecan.2016.12.005_bib0045","doi-asserted-by":"crossref","first-page":"6624","DOI":"10.3390\/ijms14046624","article-title":"Regulation of ovarian cancer stem cells or tumor-initiating cells","volume":"14","author":"Kwon","year":"2013","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.trecan.2016.12.005_bib0050","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.ygyno.2016.04.002","article-title":"The significance and therapeutic potential of PD-1 and its ligands in ovarian cancer: a systematic review","volume":"142","author":"Zhu","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.trecan.2016.12.005_bib0055","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1080\/15384047.2015.1040960","article-title":"Tumor infiltrating lymphocytes in ovarian cancer","volume":"16","author":"Santoiemma","year":"2015","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.trecan.2016.12.005_bib0060","article-title":"Extracellular vesicles swarm the cancer microenvironment: from tumor\u2013stroma communication to drug intervention","author":"Wendler","year":"2016","journal-title":"Oncogene"},{"key":"10.1016\/j.trecan.2016.12.005_bib0065","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.ccell.2014.09.005","article-title":"Cancer exosomes perform cell-independent microRNA biogenesis and promote tumorigenesis","volume":"26","author":"Melo","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.trecan.2016.12.005_bib0070","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S1470-2045(16)30108-5","article-title":"Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study","volume":"17","author":"Bagnoli","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.trecan.2016.12.005_bib0075","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ccr.2012.12.020","article-title":"Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer","volume":"23","author":"Yang","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.trecan.2016.12.005_bib0080","doi-asserted-by":"crossref","first-page":"dju249","DOI":"10.1093\/jnci\/dju249","article-title":"Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer","volume":"106","author":"Konecny","year":"2014","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.trecan.2016.12.005_bib0085","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1111\/cpr.12038","article-title":"Enrichment of ovarian cancer stem-like cells is associated with epithelial to mesenchymal transition through an miRNA-activated AKT pathway","volume":"46","author":"Luo","year":"2013","journal-title":"Cell Prolif."},{"key":"10.1016\/j.trecan.2016.12.005_bib0090","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.ejca.2012.06.026","article-title":"Resistance to platinum-based chemotherapy is associated with epithelial to mesenchymal transition in epithelial ovarian cancer","volume":"49","author":"Marchini","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.trecan.2016.12.005_bib0095","doi-asserted-by":"crossref","first-page":"55771","DOI":"10.18632\/oncotarget.9908","article-title":"Targeting epithelial\u2013mesenchymal transition and cancer stem cells for chemoresistant ovarian cancer","volume":"7","author":"Deng","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.trecan.2016.12.005_bib0100","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1002\/cam4.409","article-title":"Overexpression of the microRNA miR-433 promotes resistance to paclitaxel through the induction of cellular senescence in ovarian cancer cells","volume":"4","author":"Weiner-Gorzel","year":"2015","journal-title":"Cancer Med."},{"key":"10.1016\/j.trecan.2016.12.005_bib0105","doi-asserted-by":"crossref","first-page":"11150","DOI":"10.1038\/ncomms11150","article-title":"Exosomal transfer of stroma-derived miR21 confers paclitaxel resistance in ovarian cancer cells through targeting APAF1","volume":"7","author":"Au Yeung","year":"2016","journal-title":"Nature Commun."},{"key":"10.1016\/j.trecan.2016.12.005_bib0110","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.molmed.2016.07.006","article-title":"Shipping drug resistance: extracellular vesicles in ovarian cancer","volume":"22","author":"Strandmann","year":"2016","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.trecan.2016.12.005_bib0115","doi-asserted-by":"crossref","first-page":"5923","DOI":"10.1038\/onc.2015.43","article-title":"Microenvironment-induced downregulation of miR-193b drives ovarian cancer metastasis","volume":"34","author":"Mitra","year":"2015","journal-title":"Oncogene"},{"key":"10.1016\/j.trecan.2016.12.005_bib0120","doi-asserted-by":"crossref","first-page":"11406","DOI":"10.1038\/ncomms11406","article-title":"miR-424(322) reverses chemoresistance via T-cell immune response activation by blocking the PD-L1 immune checkpoint","volume":"7","author":"Xu","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.trecan.2016.12.005_bib0125","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.1158\/0008-5472.CAN-14-3098","article-title":"Chemotherapy induces programmed cell death-ligand 1 overexpression via the nuclear factor-kappaB to foster an immunosuppressive tumor microenvironment in ovarian cancer","volume":"75","author":"Peng","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.trecan.2016.12.005_bib0130","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.cell.2016.04.009","article-title":"Effector T cells abrogate stroma-mediated chemoresistance in ovarian cancer","volume":"165","author":"Wang","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.trecan.2016.12.005_bib0135","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/ijc.24401","article-title":"Interferon-gamma reverses the immunosuppressive and protumoral properties and prevents the generation of human tumor-associated macrophages","volume":"125","author":"Duluc","year":"2009","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.trecan.2016.12.005_bib0140","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ccr.2014.05.002","article-title":"Hematogenous metastasis of ovarian cancer: rethinking mode of spread","volume":"26","author":"Pradeep","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.trecan.2016.12.005_bib0145","first-page":"1645","article-title":"The role of Apaf-1, caspase-9, and bid proteins in etoposide- or paclitaxel-induced mitochondrial events during apoptosis","volume":"60","author":"Perkins","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/j.trecan.2016.12.005_bib0150","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","author":"Cancer Genome Atlas Research Network","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2016.12.005_bib0155","doi-asserted-by":"crossref","first-page":"4","DOI":"10.5732\/cjc.014.10289","article-title":"The PI3K\/Akt\/mTOR pathway in ovarian cancer: therapeutic opportunities and challenges","volume":"34","author":"Cheaib","year":"2015","journal-title":"Chin. J. Cancer"},{"key":"10.1016\/j.trecan.2016.12.005_bib0160","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/ijc.28335","article-title":"Mixed-polarization phenotype of ascites-associated macrophages in human ovarian carcinoma: correlation of CD163 expression, cytokine levels and early relapse","volume":"134","author":"Reinartz","year":"2014","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.trecan.2016.12.005_bib0165","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1038\/nrc3818","article-title":"Revisiting STAT3 signalling in cancer: new and unexpected biological functions","volume":"14","author":"Yu","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.trecan.2016.12.005_bib0170","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/j.celrep.2016.04.034","article-title":"Direct upregulation of STAT3 by microRNA-551b-3p deregulates growth and metastasis of ovarian cancer","volume":"15","author":"Chaluvally-Raghavan","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.trecan.2016.12.005_bib0175","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1111\/j.1440-1827.2008.02306.x","article-title":"Increased staining for phosphorylated AKT and nuclear factor-kappaB p65 and their relationship with prognosis in epithelial ovarian cancer","volume":"58","author":"Guo","year":"2008","journal-title":"Pathol. Int."},{"key":"10.1016\/j.trecan.2016.12.005_bib0180","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1111\/j.1365-2559.2010.03544.x","article-title":"Expression of classical NF-kappaB pathway effectors in human ovarian carcinoma","volume":"56","author":"Darb-Esfahani","year":"2010","journal-title":"Histopathology"},{"key":"10.1016\/j.trecan.2016.12.005_bib0185","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/gm177","article-title":"Recent insights into the role of NF-kappaB in ovarian carcinogenesis","volume":"2","author":"Alvero","year":"2010","journal-title":"Genome Med."},{"key":"10.1016\/j.trecan.2016.12.005_bib0190","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.4049\/jimmunol.175.2.1197","article-title":"Macrophages induce invasiveness of epithelial cancer cells via NF-kappa B and JNK","volume":"175","author":"Hagemann","year":"2005","journal-title":"J. Immunol."},{"key":"10.1016\/j.trecan.2016.12.005_bib0195","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1158\/0008-5472.CAN-11-2178","article-title":"A dynamic inflammatory cytokine network in the human ovarian cancer microenvironment","volume":"72","author":"Kulbe","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.trecan.2016.12.005_bib0200","doi-asserted-by":"crossref","first-page":"4139","DOI":"10.1038\/onc.2011.572","article-title":"Ligand-dependent EGFR activation induces the co-expression of IL-6 and PAI-1 via the NFkB pathway in advanced-stage epithelial ovarian cancer","volume":"31","author":"Alberti","year":"2012","journal-title":"Oncogene"},{"key":"10.1016\/j.trecan.2016.12.005_bib0205","doi-asserted-by":"crossref","first-page":"120","DOI":"10.3389\/fonc.2013.00120","article-title":"Targeting nuclear factor-kappa B to overcome resistance to chemotherapy","volume":"3","author":"Godwin","year":"2013","journal-title":"Front. Oncol."},{"key":"10.1016\/j.trecan.2016.12.005_bib0210","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ccr.2009.02.015","article-title":"Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors","volume":"15","author":"Lee","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.trecan.2016.12.005_bib0215","first-page":"283181","article-title":"Integrin signaling in cancer cell survival and chemoresistance","volume":"2012","author":"Aoudjit","year":"2012","journal-title":"Chemother. Res. Pract."},{"key":"10.1016\/j.trecan.2016.12.005_bib0220","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s10555-012-9351-2","article-title":"Cell-cell and cell-matrix dynamics in intraperitoneal cancer metastasis","volume":"31","author":"Sodek","year":"2012","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.trecan.2016.12.005_bib0225","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.cell.2016.05.069","article-title":"Integrated proteogenomic characterization of human high-grade serous ovarian cancer","volume":"166","author":"Zhang","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.trecan.2016.12.005_bib0230","doi-asserted-by":"crossref","first-page":"25","DOI":"10.4161\/cbt.13.1.18440","article-title":"Inhibition of the Rho\/ROCK pathway enhances the efficacy of cisplatin through the blockage of hypoxia-inducible factor-1alpha in human ovarian cancer cells","volume":"13","author":"Ohta","year":"2012","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.trecan.2016.12.005_bib0235","doi-asserted-by":"crossref","first-page":"24187","DOI":"10.3390\/ijms141224187","article-title":"The involvement of RhoA and Wnt-5a in the tumorigenesis and progression of ovarian epithelial carcinoma","volume":"14","author":"Chen","year":"2013","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.trecan.2016.12.005_bib0240","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s12885-016-2123-6","article-title":"MiR-193b promotes autophagy and non-apoptotic cell death in oesophageal cancer cells","volume":"16","author":"Nyhan","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.trecan.2016.12.005_bib0245","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.tips.2014.05.007","article-title":"Getting Syk: spleen tyrosine kinase as a therapeutic target","volume":"35","author":"Geahlen","year":"2014","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.trecan.2016.12.005_bib0250","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ccell.2015.05.009","article-title":"Inhibition of spleen tyrosine kinase potentiates paclitaxel-induced cytotoxicity in ovarian cancer cells by stabilizing microtubules","volume":"28","author":"Yu","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.trecan.2016.12.005_bib0255","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.febslet.2012.01.055","article-title":"Activation of spleen tyrosine kinase is required for TNF-alpha-induced endothelin-1 upregulation in human aortic endothelial cells","volume":"586","author":"Kim","year":"2012","journal-title":"FEBS Lett."},{"key":"10.1016\/j.trecan.2016.12.005_bib0260","doi-asserted-by":"crossref","first-page":"479","DOI":"10.3109\/10715761003667554","article-title":"Reactive oxygen species in cancer","volume":"44","author":"Liou","year":"2010","journal-title":"Free Radic. Res."},{"key":"10.1016\/j.trecan.2016.12.005_bib0265","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.1158\/1078-0432.CCR-12-0056","article-title":"Multidrug resistance-linked gene signature predicts overall survival of patients with primary ovarian serous carcinoma","volume":"18","author":"Gillet","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2016.12.005_bib0270","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/j.ymthe.2004.08.013","article-title":"Characterization of intraperitoneal, orthotopic, and metastatic xenograft models of human ovarian cancer","volume":"10","author":"Shaw","year":"2004","journal-title":"Mol. Ther."},{"key":"10.1016\/j.trecan.2016.12.005_bib0275","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1093\/carcin\/21.4.585","article-title":"Development of a syngeneic mouse model for events related to ovarian cancer","volume":"21","author":"Roby","year":"2000","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.trecan.2016.12.005_bib0280","doi-asserted-by":"crossref","first-page":"7419","DOI":"10.1038\/ncomms8419","article-title":"Characterization of twenty-five ovarian tumour cell lines that phenocopy primary tumours","volume":"6","author":"Ince","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.trecan.2016.12.005_bib0285","doi-asserted-by":"crossref","first-page":"3619","DOI":"10.1038\/onc.2013.321","article-title":"Epithelial ovarian cancer experimental models","volume":"33","author":"Lengyel","year":"2014","journal-title":"Oncogene"},{"key":"10.1016\/j.trecan.2016.12.005_bib0290","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.ccr.2013.10.013","article-title":"Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten models","volume":"24","author":"Perets","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.trecan.2016.12.005_bib0295","doi-asserted-by":"crossref","DOI":"10.1101\/pdb.prot090704","article-title":"Generation of genetically modified mice using the CRISPR-Cas9 genome-editing system","author":"Henao-Mejia","year":"2016","journal-title":"Cold Spring Harb. Protoc."},{"key":"10.1016\/j.trecan.2016.12.005_bib0300","first-page":"11","article-title":"Changes in ovarian tumor cell number, tumor vasculature, and T cell function monitored in vivo using a novel xenograft model","volume":"13","author":"Yokota","year":"2013","journal-title":"Cancer Immun."},{"key":"10.1016\/j.trecan.2016.12.005_bib0305","doi-asserted-by":"crossref","first-page":"e24420","DOI":"10.1371\/journal.pone.0024420","article-title":"Humanized mouse model of ovarian cancer recapitulates patient solid tumor progression, ascites formation, and metastasis","volume":"6","author":"Bankert","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.trecan.2016.12.005_bib0310","doi-asserted-by":"crossref","first-page":"4614","DOI":"10.1172\/JCI74778","article-title":"Mesothelial cells promote early ovarian cancer metastasis through fibronectin secretion","volume":"124","author":"Kenny","year":"2014","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.trecan.2016.12.005_bib0315","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.cell.2015.08.016","article-title":"Metabolic competition in the tumor microenvironment is a driver of cancer progression","volume":"162","author":"Chang","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.trecan.2016.12.005_bib0320","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1038\/nm.3931","article-title":"CD47 blockade triggers T cell-mediated destruction of immunogenic tumors","volume":"21","author":"Liu","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.trecan.2016.12.005_bib0325","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/liv.12963","article-title":"Anti-CD47 antibody suppresses tumour growth and augments the effect of chemotherapy treatment in hepatocellular carcinoma","volume":"36","author":"Lo","year":"2016","journal-title":"Liver Int."},{"key":"10.1016\/j.trecan.2016.12.005_bib0330","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s40425-015-0051-7","article-title":"Immunotherapeutic approaches to ovarian cancer treatment","volume":"3","author":"Chester","year":"2015","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.trecan.2016.12.005_bib0335","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1038\/nm.2492","article-title":"Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth","volume":"17","author":"Nieman","year":"2011","journal-title":"Nat. Med."},{"key":"10.1016\/j.trecan.2016.12.005_bib0340","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nature14410","article-title":"Whole-genome characterization of chemoresistant ovarian cancer","volume":"521","author":"Patch","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2016.12.005_bib0345","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.4161\/auto.28577","article-title":"DIRAS3 regulates the autophagosome initiation complex in dormant ovarian cancer cells","volume":"10","author":"Lu","year":"2014","journal-title":"Autophagy"},{"key":"10.1016\/j.trecan.2016.12.005_bib0350","doi-asserted-by":"crossref","first-page":"e84941","DOI":"10.1371\/journal.pone.0084941","article-title":"Ovarian cancer spheroid cells with stem cell-like properties contribute to tumor generation, metastasis and chemotherapy resistance through hypoxia-resistant metabolism","volume":"9","author":"Liao","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.trecan.2016.12.005_bib0355","doi-asserted-by":"crossref","first-page":"26788","DOI":"10.1038\/srep26788","article-title":"Stemness and chemoresistance in epithelial ovarian carcinoma cells under shear stress","volume":"6","author":"Ip","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.trecan.2016.12.005_bib0360","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/carcin\/bgr241","article-title":"Modulation of AKT activity is associated with reversible dormancy in ascites-derived epithelial ovarian cancer spheroids","volume":"33","author":"Correa","year":"2012","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.trecan.2016.12.005_bib0365","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa020177","article-title":"Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer","volume":"348","author":"Zhang","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2016.12.005_bib0370","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ygyno.2011.09.039","article-title":"Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis","volume":"124","author":"Hwang","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.trecan.2016.12.005_bib0375","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/nm1093","article-title":"Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival","volume":"10","author":"Curiel","year":"2004","journal-title":"Nat. Med."},{"key":"10.1016\/j.trecan.2016.12.005_bib0380","doi-asserted-by":"crossref","first-page":"18538","DOI":"10.1073\/pnas.0509182102","article-title":"Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+\/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer","volume":"102","author":"Sato","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.trecan.2016.12.005_bib0385","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/nature13988","article-title":"Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens","volume":"515","author":"Gubin","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2016.12.005_bib0390","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1158\/1078-0432.CCR-12-2199","article-title":"PD-L1 on tumor cells is induced in ascites and promotes peritoneal dissemination of ovarian cancer through CTL dysfunction","volume":"19","author":"Abiko","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2016.12.005_bib0395","doi-asserted-by":"crossref","first-page":"4917","DOI":"10.1158\/1078-0432.CCR-12-1972","article-title":"Molecular pathways: coexpression of immune checkpoint molecules: signaling pathways and implications for cancer immunotherapy","volume":"19","author":"Nirschl","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2016.12.005_bib0400","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.1200\/JCO.2015.62.3397","article-title":"Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer","volume":"33","author":"Hamanishi","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2016.12.005_bib0405","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s40661-016-0033-6","article-title":"The role of immune checkpoint inhibition in the treatment of ovarian cancer","volume":"3","author":"Gaillard","year":"2016","journal-title":"Gynecol. Oncol. Res. Pract."},{"key":"10.1016\/j.trecan.2016.12.005_bib0410","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1158\/1078-0432.CCR-16-0100","article-title":"Is there a future for AKT inhibitors in the treatment of cancer?","volume":"22","author":"Jansen","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2016.12.005_bib0415","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1021\/acschembio.5b00945","article-title":"Strategies and approaches of targeting STAT3 for cancer treatment","volume":"11","author":"Furtek","year":"2016","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.trecan.2016.12.005_bib0420","article-title":"Elevated STAT3 expression in ovarian cancer ascites promotes invasion and metastasis: a potential therapeutic target","author":"Saini","year":"2016","journal-title":"Oncogene"},{"key":"10.1016\/j.trecan.2016.12.005_bib0425","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2174\/156800911794519752","article-title":"Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives","volume":"11","author":"Chen","year":"2011","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.trecan.2016.12.005_bib0430","doi-asserted-by":"crossref","first-page":"5943","DOI":"10.1200\/JCO.2005.16.006","article-title":"Phase I trial of bortezomib and carboplatin in recurrent ovarian or primary peritoneal cancer","volume":"23","author":"Aghajanian","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2016.12.005_bib0435","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1097\/IGC.0b013e318251051a","article-title":"An open-label phase 2 study of twice-weekly bortezomib and intermittent pegylated liposomal doxorubicin in patients with ovarian cancer failing platinum-containing regimens","volume":"22","author":"Parma","year":"2012","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.trecan.2016.12.005_bib0440","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1756-8722-7-7","article-title":"Interferon-gamma-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines","volume":"7","author":"Niewerth","year":"2014","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.trecan.2016.12.005_bib0445","doi-asserted-by":"crossref","first-page":"26347","DOI":"10.18632\/oncotarget.4713","article-title":"IKK inhibition increases bortezomib effectiveness in ovarian cancer","volume":"6","author":"Singha","year":"2015","journal-title":"Oncotarget"}],"container-title":["Trends in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405803316302096?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405803316302096?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,4]],"date-time":"2018-09-04T21:20:03Z","timestamp":1536096003000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405803316302096"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":89,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["S2405803316302096"],"URL":"https:\/\/doi.org\/10.1016\/j.trecan.2016.12.005","relation":{},"ISSN":["2405-8033"],"issn-type":[{"value":"2405-8033","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tumor\u2013Host Cell Interactions in Ovarian Cancer: Pathways to Therapy Failure","name":"articletitle","label":"Article Title"},{"value":"Trends in Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trecan.2016.12.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}